key
compon
ubiquitinproteasomesystem
up
fundament
role
dub
specif
remov
ubiquitin
substrat
dub
contribut
activationdeactiv
recycl
local
numer
regulatoryprotein
thu
play
major
role
divers
cellularprocess
alter
dub
activ
associ
multitud
patholog
includ
cancer
therefor
dub
repres
novel
candid
targetdirect
drug
develop
area
coveredth
articl
thorough
reviewaccount
patent
compound
target
dub
stratifyingclassifi
patent
compound
base
chemicalstructur
nucleicacid
composit
modesofact
targetingsit
review
provid
brief
background
up
dub
involv
furthermor
method
assess
efficaci
potenti
pharmacolog
util
dub
inhibitor
dubi
discuss
expert
opinionth
fda
approv
proteasom
inhibitor
bortezomib
carfilzomib
treatment
hematolog
malign
establish
up
anticanc
target
unfortun
mani
patient
inher
resist
develop
resist
proteasom
inhibitor
pi
one
potenti
strategi
combat
pi
resist
target
upstream
compon
up
dub
dub
repres
promis
potenti
therapeut
target
due
critic
role
variou
cellular
process
includ
proteinturnov
local
cellular
homeostasi
consider
effort
undertaken
develop
dub
modul
signific
advanc
necessari
move
dub
inhibitor
clinic
up
consist
seri
enzymat
reaction
wherein
ubiquitin
amino
acid
polypeptid
conjug
onto
specif
lysin
residu
varieti
protein
substrat
via
conjug
approxim
ubiquitin
ligas
identifi
variabl
specif
individu
proteinsubstr
protein
polyubiquitin
ligas
design
degrad
unmodifi
up
condit
transport
multimer
proteasom
complex
cleav
oligopeptid
releas
ubiquitin
moieti
recycl
up
proteasom
consist
complex
core
particl
consist
heteromer
possess
proteaselik
activ
cap
two
regulatori
particl
end
core
detail
descript
up
compon
pleas
refer
follow
review
importantli
aberr
proteasom
activ
extens
associ
variou
patholog
includ
limit
cancer
multipl
neurolog
disord
led
extens
interest
molecular
machineri
regul
up
modul
proteinubiquitin
state
fate
ubiquitin
protein
determin
number
ubiquitin
residu
ubchain
posit
conjug
specif
branch
pattern
polyubiquitin
chain
protein
ubiquitin
ub
revers
mechan
deubiquitin
regul
dub
emerg
cardin
regulatorytarget
posttransl
modif
like
protein
phosphoryl
add
complex
sensit
up
complex
natur
up
modul
allow
cell
fine
tune
respons
differ
physiolog
state
stimuli
modul
fate
key
molecul
cell
molecularmachinerysystem
biologicalpathway
ubiquitin
statu
recogn
key
posttransl
modif
play
plethora
critic
role
protein
turnov
well
varieti
signal
transduct
pathway
regul
degrad
consequ
express
activ
plethora
critic
molecular
target
result
dub
regul
divers
cellular
process
function
figur
includ
process
remov
polyubiquitin
moieti
chain
protein
therebi
alter
target
protein
fate
regard
either
degrad
proteasom
andor
differenti
subcellular
local
addit
dub
regul
gene
express
apoptosi
cell
cycl
dna
repair
well
cytokin
signal
discuss
dub
diseas
section
generationreleas
free
ubiquitin
de
novo
ub
synthesi
cleavag
polyubiquitin
chain
complet
remov
ubiquitin
chain
ubiquitin
protein
ubiquitin
transcrib
linear
fusion
multipl
ubiquitin
moieti
ribosom
dub
activ
gener
free
ubiquitin
interestingli
process
could
perform
concurr
translat
fundament
aspect
dub
activ
process
gener
de
novo
ub
up
dubmedi
cleavag
polyubiquitin
chain
work
via
similar
mechan
protein
phosphatas
releas
phosphoryl
group
kinasephosphatas
network
thu
dub
ligas
regul
protein
fate
similar
way
kinas
phosphatas
regul
protein
activ
howev
complex
up
far
exceed
kinasephosphatas
dynam
mention
previous
ubiquitin
chain
differ
length
andor
branch
pattern
modul
local
degrad
ubiquitin
protein
therefor
specif
cleavag
along
ubiquitin
chain
differ
locat
differenti
effect
fate
ubiquitin
protein
provid
cell
complex
dynam
system
modul
protein
turnov
activ
express
local
complet
remov
ubiquitin
chain
ubiquitin
protein
gener
result
protein
stabil
prevent
up
degrad
may
also
affect
local
protein
depend
target
proteinubiquitin
system
either
event
activ
dub
alway
releas
ub
moieti
complet
incomplet
recycl
up
maintain
state
ubiquitin
homeostasi
substanti
scientif
evid
demonstr
dub
exhibit
strong
substrat
select
includ
protein
specif
specif
specif
branch
patter
motif
polyubiquitin
chain
key
domain
dub
ubiquitinbind
domain
ubd
ubd
consist
ubiquitininteract
motif
uim
zinc
finger
ubiquitinspecif
proteas
domain
znfubp
domain
ubiquitinassoci
domain
uba
domain
research
indic
znfubp
impart
abil
dub
specif
target
individu
protein
andor
structuralmotif
therebi
impart
target
specif
individu
dub
hypothes
almost
dub
encod
human
genom
dub
subdivid
five
subfamili
consist
four
cystein
proteas
ubiquitinspecif
proteas
usp
ubiquitin
ctermin
hydrolas
uch
ovarion
tumour
proteas
otu
machadojoseph
domain
proteas
mjd
zinc
metalloisopeptidas
herp
viru
tegument
usp
eg
metalloproteasesjamm
addit
usp
novel
class
proteas
function
dub
gene
famili
also
report
suggest
may
gene
famili
act
up
modul
protein
ubiquitin
statu
consid
designingdevelop
dub
inhibitor
target
therapi
among
dub
three
dub
associ
regulatori
particl
rp
human
includ
bortezomib
proteasom
inhibitor
pi
approv
fda
treatment
multipl
myeloma
mm
mantl
cell
lymphoma
inhibit
proteasom
bortezomib
first
clinic
valid
target
up
cancer
therapeut
howev
soon
observ
extend
treatment
bortezomib
associ
toxic
drug
resist
limit
efficaci
furthermor
pi
fail
show
efficaci
solid
tumor
human
research
propos
target
specif
aspect
ubiquitinproteasom
pathway
upstream
proteasom
eg
dub
might
advantag
regard
efficaci
well
advers
effect
aspect
dub
activ
make
attract
therapeut
target
cancer
diseas
abil
modul
protein
fate
specif
select
mannerfashion
therefor
target
pathway
modul
signal
statu
cell
modifi
specif
key
aspect
patholog
pathway
specif
direct
cell
toward
death
recov
patholog
state
exampl
dub
target
tumor
suppressor
protein
may
good
target
activ
order
increas
express
tumor
suppressor
decreas
up
degrad
altern
target
dub
may
chang
local
protein
serv
inhibit
oncogen
process
convers
dub
target
oncogen
protein
may
target
compound
inhibit
activ
degrad
up
develop
design
enzym
selectivespecif
inhibitor
easier
design
develop
enzym
activ
due
competit
inhibit
model
substrat
therefor
research
emphas
greater
effort
toward
develop
dub
inhibitor
howev
import
emphas
benefit
studi
basic
scienc
modul
complex
system
order
determin
intrins
mechan
enhanc
select
dub
activ
endogen
could
potenti
highjackutil
process
properti
design
therapi
around
natur
stratagem
usp
uch
subfamili
dub
rel
well
character
fortun
crystal
structur
mani
dub
uspubp
class
eg
resolv
lead
molecular
recognit
profil
studi
proteas
activ
ubiquitin
ubiquitin
aldehydecomplex
state
type
studi
support
rational
design
develop
dub
inhibitor
furthermor
genom
studi
identifi
least
addit
gene
might
involv
deconjug
ubiquitin
molecul
propos
least
gene
set
encod
function
dub
multipl
potenti
isoform
process
ubiquitin
conjug
studi
extens
contrast
studi
deubiquitn
activ
dub
still
preliminari
stage
interestingli
earli
studi
suggest
number
dub
unp
ubpi
play
promin
role
cancer
develop
progress
thought
involv
differ
cancer
includ
limit
ovarian
colorect
cancer
screen
genet
abnorm
ovarian
cancer
cell
line
vitro
well
focu
format
assay
point
role
ovarian
carcinogenesi
anoth
studi
colorect
cancer
patient
found
upregul
express
level
associ
patholog
stage
well
liver
lymph
node
metastas
degrad
chemotaxi
control
due
deubiquitin
anoth
studi
suggest
regul
nuclear
well
signal
overexpress
result
enhanc
cell
prolifer
knockdown
led
apoptosi
lung
cancer
cell
tumor
sampl
patient
esophag
squamou
cell
carcinoma
analyz
direct
correl
upregul
level
lymph
node
metastasi
found
inhibit
dub
act
oncoprotein
well
activ
degrad
inhibit
dub
serv
tumor
suppressor
could
promis
therapeut
strategi
ubpi
varieti
substrat
includ
epiderm
growth
factor
receptor
egfr
lead
degrad
inde
inhibit
either
knockdown
synthet
small
molecul
led
attenu
varieti
receptor
tyrosin
kinas
rtk
activ
result
inhibit
cell
prolifer
gefitinibresist
sensit
nonsmal
cell
lung
cancer
nsclc
cell
furthermor
shown
highli
express
mm
cell
compar
normal
plasma
cell
addit
knockdown
sirna
decreas
mm
cell
viabil
bind
revers
rp
implic
cancer
therefor
inhibit
could
lead
decreas
uptak
protein
substrat
destin
degrad
studi
led
identif
variou
dub
inhibitor
eg
discuss
detail
section
novel
inhibitor
regulatori
particl
select
block
deubiquitin
activ
without
compromis
proteolyt
activ
core
particl
although
variou
dub
inhibitor
report
last
decad
still
preclin
phase
use
research
tool
therefor
depth
studi
warrant
dub
inhibitor
modul
order
develop
clinic
purpos
dub
implic
numer
patholog
includ
neurolog
disord
autoimmun
inflamm
microbi
infect
howev
precis
mechan
dub
contribut
neurolog
disord
still
unclear
exampl
shown
mutat
human
play
major
role
ataxia
howev
mechan
understood
variou
studi
shown
conflict
result
whether
allel
give
protect
sporad
parkinson
diseas
risk
factor
shown
elev
locat
chromosom
partli
involv
syndrom
phenotyp
mani
bacteria
eg
burkholderia
mallei
salmonella
virus
eg
sar
coronaviru
plpro
herp
viru
exploit
host
cell
machineri
express
multifunct
proteas
target
multipl
host
ubl
ubiquitin
advantag
infect
pathogenesi
host
cell
multifunct
enzym
structur
differ
human
dub
qualiti
could
exploit
design
develop
select
inhibitor
pathogen
dub
deubiquitin
otu
domain
contain
protein
regul
activ
signal
deregul
activ
associ
prolong
inflamm
autoimmun
disord
interestingli
variou
mutat
gene
detect
associ
autoimmun
disord
human
lymphoma
also
mani
dub
includ
brcacontain
complex
regul
chromatin
structur
gene
express
target
histon
mainli
evid
suggest
aberr
dub
activ
lead
alter
gene
silenc
cell
cycl
repair
dna
damag
extens
search
highlypot
irrevers
dub
inhibitor
result
identif
ubal
ubiquitin
aldehyd
ubv
ubiquitin
vinyl
sulfon
unfortun
due
peptid
natur
high
molecular
weight
lack
specif
agent
pharmacolog
viabl
clinic
howev
still
use
research
tool
studi
dub
normal
cell
cancer
well
viral
infect
cell
inde
ubv
ubal
use
imag
studi
three
dimension
structur
function
activ
dub
uch
protein
major
role
recycl
ubiquitin
molecul
remov
ctermin
adduct
therefor
effort
taken
design
develop
inhibitor
led
identif
compound
isatin
oacyl
oxim
seri
figur
compound
ac
competit
revers
direct
compound
target
activ
site
ic
valu
micromolar
rang
approxim
higher
select
inhibit
cell
prolifer
lung
neuroblastoma
cell
line
cell
line
treat
inhibitor
enhanc
cell
prolifer
observ
support
antiprolif
role
enzym
anoth
set
compound
dihydropyrrol
backbon
low
micromolar
ic
valu
identifi
figur
compound
df
probabl
bind
site
activ
site
competit
mode
bind
similarli
isatin
deriv
figur
compound
gi
show
higher
select
enzym
compound
h
h
ic
ubiquitinpest
z
benzyloxycarbonyl
lrggamc
use
substrat
identifi
inhibitor
cellular
dub
cyclopentenon
prostaglandin
result
compound
induc
apoptosi
colon
cancer
cell
accumul
ubiquitin
protein
note
compound
lack
specif
inhibit
wide
rang
dub
commerci
sourc
like
hybrigen
develop
high
throughput
screen
assay
use
ubiquitin
deriv
well
specif
usp
substrat
screen
divers
set
chemic
order
find
inhibitor
although
limit
factor
work
lack
specif
identifi
inhibitor
research
shown
select
inhibit
specif
dub
possibl
figur
novel
proteasomeinhibitori
agent
act
abrog
dub
activ
associ
rp
select
inhibit
activ
two
dub
associ
rp
affect
nonproteasom
dub
inventor
propos
may
effect
treat
cancer
subtyp
resist
bortezomib
pi
furthermor
research
show
compound
may
effect
treatment
anticanc
agent
refractori
cancer
induc
accumul
higher
molecular
weight
polyubiquin
protein
rel
bortezomib
lead
enhanc
unfold
protein
respons
upr
interestingli
statu
cancer
cell
overexpress
antiapoptot
protein
bax
puma
affect
induct
apoptosi
therefor
moa
differ
bortezomib
also
decreas
viabil
mm
cell
line
well
mm
cell
obtain
patient
even
presenc
bone
marrow
stroma
cell
importantli
vitro
condit
shown
overcom
bortezomib
resist
treatment
mm
cell
arrest
growth
due
regul
cyclin
induct
caspasedepend
apoptosi
activ
unfold
protein
respons
well
toler
invivo
studi
use
human
mm
xenograft
model
associ
inhibit
tumor
growth
well
prolong
surviv
combin
suberoylanilid
hydroxam
acid
lenalidomid
dexamethason
show
synergist
antimm
activ
induc
apoptosi
depend
statu
express
cancer
cell
preclin
data
demonstr
efficaci
mm
diseas
model
valid
dub
potenti
therapeut
target
provid
basi
futur
clinic
studi
inhibitor
patient
resist
pi
neck
carcinoma
well
infiltr
acut
myeloid
leukemia
aml
model
predict
use
treatment
multipl
myeloma
solid
tumor
malign
like
breast
lung
colon
pancrea
head
neck
prostat
pancrea
ovarian
cancer
therefor
may
use
context
figur
small
molecular
weight
anticanc
agent
inhibit
signal
suppress
hypoxia
induc
factor
protein
level
via
inhibit
deubiquitinas
activ
nbi
chloroethyl
amino
phenyl
propion
acid
noxid
dihydrochlorid
melphalan
noxid
inventor
found
effect
associ
increas
level
polyubiquitin
degrad
independ
known
pathway
regul
inhibit
also
associ
inhibit
cytoplasm
deubiquitinas
activ
compound
decreas
hypoxiainduc
increas
protein
inhibit
transactiv
decreas
express
downstream
target
gene
vascular
endotheli
growth
factor
vegf
induc
nitric
oxid
synthas
ino
sever
cancer
cell
line
inventor
demonstr
act
independ
von
hippel
lindeau
protein
pvhl
pathway
howev
inventor
identifi
dub
target
import
cancer
base
fact
protein
found
wide
varieti
human
primari
tumor
low
level
normal
tissu
exemplifi
high
incid
tumor
renal
cell
carcinoma
pheochromocytoma
hemingioblastoma
central
nervou
system
individu
loss
function
allel
vhl
gene
lead
elev
level
addit
case
sporad
renal
cell
carcinoma
associ
earli
loss
function
hvl
gene
increas
level
level
also
increas
cancer
cell
mutant
delet
pten
therefor
describ
import
target
anticanc
drug
develop
role
play
regul
respons
grow
tumor
hypoxia
agent
would
effect
tumor
select
activ
hypox
environ
heterocycl
compound
tricycl
structur
repres
common
structur
formula
shown
figur
w
x
z
denot
differ
organ
speci
substitu
defin
inventor
compound
shown
figur
demonstr
highest
inhibit
activ
tabl
compound
enhanc
proteasom
activ
inhibit
deubiquitin
activ
therebi
enhanc
degrad
abnorm
misfold
protein
includ
associ
human
diseas
inventor
suggest
enhanc
proteasom
activ
could
benefici
proteinopathi
might
also
therapeut
diseas
character
defici
proteasom
activ
defici
activ
compon
ubiquitinproteasom
pathway
von
hippellindau
diseas
angelman
syndrom
spinocerebellar
ataxia
giant
axon
neuropathi
inclus
bodi
myopathi
paget
diseas
bone
frontotempor
dementia
ibmpfd
case
cancer
suggest
varieti
oncoprotein
proteasom
substrat
enhanc
proteasom
activ
abil
promot
tumorigenesi
could
potenti
inhibit
invent
compound
gener
structur
shown
figur
potenti
novel
class
proteasom
inhibitor
known
compound
repres
figur
letter
r
x
repres
chemic
configur
substitu
figur
explain
inventor
simpl
repres
exampl
figur
similar
mode
action
exert
set
compound
inhibit
activ
two
dub
associ
rp
affect
nonproteasom
dub
inventor
describ
effect
mean
treatment
cancer
refractori
convent
chemotherapi
due
overexpress
intrins
apoptosisinhibitor
particularli
cancer
refractori
bortezomib
agent
share
mechan
bortezomib
exampl
cancer
type
amen
treatment
compound
given
multipl
myeloma
solid
tumor
malign
like
lung
prostat
colon
ovari
pancrea
breast
neck
head
cancer
disclos
compound
use
dub
inhibitor
method
use
compound
may
repres
one
exampl
name
wpi
whose
chemic
structur
shown
figur
pr
indic
npropyl
group
wpi
small
molecul
dub
inhibitori
activ
rapidli
induc
ubiquitin
bcrabl
result
reloc
cytoplasm
compact
intracellular
protein
complex
call
aggresom
modif
result
loss
downstream
bcrabl
oncogen
signal
compound
also
directli
inhibit
deubiquitinas
recent
report
regul
stabil
mcll
antiapoptot
protein
express
mani
tumor
includ
hematolog
malign
mcll
associ
drug
resist
surviv
hematopoiet
malign
wpl
inhibit
associ
reduc
mcll
level
togeth
block
bcrabl
kinas
signal
result
rapid
onset
apoptosi
inventor
result
wpi
suggest
target
specif
ubiquitin
cycl
regul
may
emerg
novel
therapeut
approach
inhibit
oncoprotein
signal
reduc
elev
apoptot
threshold
disclos
compound
method
use
inhibit
dub
inhibit
uch
catalyt
domain
inhibit
prevent
pathogen
infect
inhibit
surviv
prolifer
cell
treat
neurodegen
disord
treat
one
symptom
neurodegen
disord
treat
one
symptom
genet
disord
compound
inhibit
dub
method
compound
also
use
treat
cancer
eg
prevent
inhibit
andor
amelior
cancer
symptom
cancer
case
method
treat
cancer
compris
inhibit
dub
eg
dub
involv
surviv
prolifer
cancer
invent
provid
method
synthes
compound
gener
formula
repres
figur
wherein
r
select
aryl
heteroarylaryl
heteroaryl
heterocyclyl
option
substitut
substitu
select
halo
alkyl
alkoxi
trifluoromethyl
cyano
aryl
option
substitut
aryl
heteroaryl
heterocyclyl
methylenedioxi
cycloalkyl
r
similarli
multisubstitut
r
minor
variat
r
select
hydrogen
alkyl
r
select
hydrogen
alkyl
alkoxi
amino
alkylamino
dialkylamino
alkylthio
halo
substitu
compound
function
inhibitor
deubiquitinas
complex
usp
l
uaf
l
complex
found
deubiquitin
monoubiquitin
pcna
prolifer
cell
nuclear
antigen
monoubiquitin
fanconi
anemia
group
complement
group
protein
play
import
function
transles
synthesi
tl
fanconi
anemia
fa
pathway
respect
among
human
usp
occupi
special
posit
implic
dna
damag
respons
play
import
role
two
essenti
dna
damag
respons
pathway
repres
promis
target
small
molecul
intervent
improv
efficaci
commonli
use
dna
damag
drug
modul
cell
abil
repair
toler
dna
lesion
compound
invent
exhibit
select
versu
usp
invent
claim
provid
method
inhibit
heterodimer
deubiquitinas
complex
cell
method
compris
administ
cell
effect
amount
compound
invent
accord
certain
embodi
heterodimer
deubiquitinas
complex
also
provid
method
treat
cancer
mammal
need
thereof
compris
administ
anim
compound
salt
invent
accord
embodi
compound
salt
invent
administ
mammal
ie
without
coadministr
anticanc
agent
radiat
bio
therapeut
agent
altern
invent
provid
method
enhanc
chemotherapeut
treatment
cancer
mammal
undergo
treatment
anticanc
agent
method
compris
coadminist
mammal
effect
amount
compound
invent
certain
embodi
anticanc
agent
dna
damag
agent
dna
damag
agent
suitabl
dna
damag
agent
prefer
embodi
dna
damag
agent
cisplatin
dna
damag
agent
also
radiat
biotherapeut
agent
antibodi
inventor
describ
nucleic
acid
inhibitor
dub
form
sirna
suffici
complementari
gene
sequenc
direct
rna
interfer
express
administ
cell
anoth
embodi
describ
dub
inhibitor
combin
sirna
sirna
amifostin
ubiquitin
aldehyd
biomol
invent
provid
sirna
direct
gene
caus
increas
level
pcnaub
cell
increas
level
pcnaub
dna
repair
activ
cell
nucleu
increas
increas
viabil
cell
expos
genotox
agent
ioniz
radiat
ultraviolet
light
antineoplast
agent
inhibitor
use
treat
prevent
cancer
bone
marrow
failur
damag
cell
dna
result
genotox
agent
antineoplast
agent
includ
chemotherapeut
agent
radiat
inhibitor
also
use
enhanc
cell
surviv
administ
either
radiat
exposur
method
also
provid
enhanc
chemotherapi
radiotherapi
cancer
enhanc
dna
repair
embodi
variat
use
sirna
gene
describ
patent
applic
invent
also
cover
method
identif
modul
enzymat
pathway
treatment
disord
associ
pathway
composit
investig
biolog
function
pathway
dub
subdivid
ubiquitin
ctermin
hydrolas
uch
ubiquitinspecif
process
proteas
ubp
uch
ubp
thiol
proteas
specif
ubiquitin
introduct
suitabl
electrophil
cterminu
ubiquitin
allow
irrevers
trap
uch
ubp
coval
adduct
label
probe
enabl
direct
visual
activ
dub
protein
involv
ubiquitin
deubiquitin
vinyl
sulfon
employ
appropri
electrophil
sinc
versatil
function
group
ideal
suit
inhibit
thiol
proteas
employ
ubv
probe
modif
known
put
yeast
deubiquitin
enzym
achiev
name
mammalian
cell
greater
number
polypeptid
label
dub
includ
dub
associ
mammalian
proteasom
novel
protein
mammalian
homolog
yeast
author
expati
fact
ubiquitin
pathway
shown
play
import
regulatori
role
process
cell
cycl
control
signal
transduct
immun
respons
implic
develop
cancer
neurodegen
diseas
therefor
provid
patent
repres
method
identif
modul
ubiquitin
pathway
would
serv
investig
treatment
disord
associ
pathway
assay
method
describ
substrat
measur
activ
dub
compris
diubiquitin
molecul
ubiquitin
monom
label
fluoresc
tag
method
also
serv
assay
dub
enzym
use
substrat
mechan
action
determin
enzym
activ
depend
substrat
compris
fluorescentlylabel
diubiquitin
molecul
wherein
cleavag
diubiquitin
molecul
accompani
fluoresc
anisotropi
also
refer
fluoresc
polar
forster
reson
energi
transfer
fret
fluoresc
anisotropi
measur
tumbl
rate
fluoresc
molecul
solut
latter
depend
size
shape
molecul
molecul
chang
size
diubiquitin
molecul
cleav
dub
rate
tumbl
chang
reduct
size
molecul
cleavag
chang
tumbl
rate
chang
degre
polar
emit
light
may
readili
measur
invent
provid
method
assay
activ
deubiquitin
enzym
expos
test
substrat
dub
monitor
cleavag
substrat
measur
fluoresc
polar
anisotropi
fret
embodi
invent
exist
suffici
detail
inventor
includ
one
trimer
tetram
polym
ubiquitin
may
use
variat
state
advantag
exampl
dub
assay
inhibit
ubiquitin
dimmer
invent
describ
satisfi
need
assay
dub
enzym
measur
cleavag
natur
ubiquitin
linkag
better
reflect
linkag
specif
dub
enzym
describ
invent
assay
method
identifi
modul
assay
involv
identifi
substanc
bind
modul
activ
invent
also
relat
treatment
author
manuscript
author
manuscript
cylindromatosi
gener
modul
condit
associ
activ
transcript
factor
nfkb
inflamm
gener
assay
consist
bring
put
modul
contact
test
system
compris
vhl
determin
effect
put
modul
stabil
andor
state
ubiquitin
numer
aspect
variat
basic
test
system
provid
inventor
serv
sever
relat
goal
determin
modul
product
result
determin
varieti
way
accord
system
use
includ
fluoresc
reson
energi
transfer
fret
report
gene
assay
scintil
proxim
assay
etc
activ
report
novel
target
control
sinc
loss
lead
decreas
reduct
respons
mediat
hif
convers
increas
activ
would
stabil
lead
increas
hifmedi
respons
find
stabil
regul
thu
provid
novel
assay
method
develop
new
agent
human
anim
therapi
inventor
also
identifi
regulatori
pathway
present
cell
directli
link
action
cyld
suppress
nfkb
loss
cyld
reportedli
lead
increas
nfkb
activ
caus
increas
antiapoptot
gene
function
disrupt
balanc
proand
antiapoptogen
gene
regul
skin
cell
lead
growth
benign
tumor
associ
cylidromatosi
assay
modul
transcript
factor
hif
would
use
sinc
system
key
regul
respons
hypoxia
crucial
oxygen
homeostasi
wide
rang
organ
inventor
mention
instanc
larg
number
transcript
target
identifi
critic
role
angiogenesi
erythropoiesi
energi
metabol
inflamm
vasomotor
function
apoptoticprolif
respons
hif
also
import
cancer
commonli
upregul
major
effect
tumor
growth
angiogenesi
invent
also
provid
method
treat
individu
cylindromatosi
administ
individu
effect
amount
nfkb
inhibitor
present
invent
relat
field
detect
activ
isopeptidas
specif
present
invent
provid
materi
method
improv
sensit
fluoresc
eg
intern
quench
fluoresc
technolog
detect
isopeptidas
deubiquitin
enzym
ubiquitinlik
protein
deconjugas
use
diubiquitin
protein
substrat
measur
isopeptidas
activ
deubiquitinas
diubiquitin
measur
isopeptidas
activ
deubiquitinas
compris
first
ubiquitin
molecul
oper
link
least
one
first
energi
transfer
pair
member
b
second
ubiquitin
molecul
oper
link
least
one
second
energi
transfer
pair
member
wherein
said
first
ubiquitin
molecul
oper
link
said
second
ubiquitin
molecul
isopeptid
bond
cterminu
said
first
ubiquitin
molecul
side
chain
lysin
residu
said
second
ubiquitin
molecul
wherein
said
first
second
energi
transfer
pair
member
individu
either
fluoresc
group
quench
group
ub
suitabl
method
substrat
present
invent
come
speci
includ
without
limit
human
yeast
ubiquitin
use
substrat
method
present
invent
detect
activ
cognat
isopeptidas
particular
embodi
ub
moieti
diubiquitin
matur
form
protein
ie
form
protein
precursor
process
hydrolas
peptidas
particular
embodi
ub
mammalian
ubiquitin
particularli
human
ubiquitin
inventor
disclos
diand
polyubiquitin
deubiquitinas
substrat
use
thereof
specif
invent
provid
materi
method
improv
sensit
fluoresc
eg
intern
quench
floresc
technolog
detect
isopeptidas
deubiquitin
enzym
ubiquitinlik
protein
deconjugas
use
diubiquitin
protein
substrat
diubiquitin
employ
measur
isopeptidas
activ
deubiquitinas
particular
embodi
diubiquitin
compris
first
ubiquitin
molecul
oper
link
least
one
first
energi
transfer
pair
member
second
ubiquitin
molecul
oper
link
least
one
second
energi
transfer
pair
member
wherein
said
first
ubiquitin
molecul
oper
link
second
ubiquitin
molecul
isopeptid
bond
cterminu
first
ubiquitin
molecul
side
chain
lysin
residu
second
ubiquitin
molecul
first
second
energi
transfer
pair
member
may
individu
either
fluoresc
quench
group
method
compris
contact
sampl
least
one
diubiquitin
instant
invent
detect
fluoresc
sampl
wherein
chang
fluoresc
indic
isopeptidas
activ
method
perform
presenc
absenc
test
compound
screen
compound
abil
modul
activ
least
one
isopeptidas
invent
provid
method
correspond
reagent
improv
method
fluoresc
detect
isopeptidas
activ
method
substrat
invent
use
detectmeasur
activ
presenc
wide
varieti
enzym
particularli
isopeptidas
one
isopeptidas
substrat
may
use
isopeptidas
activ
detect
isopeptidas
includ
deubiquitin
enzym
ubiquitinlik
protein
ubl
specif
proteas
ulp
particular
embodi
isopeptidas
deubiquitinas
method
present
invent
practic
use
sampl
activ
isopeptidas
detect
sampl
may
varieti
sourc
includ
anim
plant
cell
cellular
lysat
vitro
reaction
mixtur
drug
screen
purpos
includ
solut
andor
mixtur
contain
recombinantli
produc
isopeptidas
bodili
fluid
tissu
sampl
taken
anim
human
eg
biolog
sampl
invent
also
provid
method
diagnos
diseas
condit
associ
particular
ubor
ublspecif
isopeptidas
sampl
subject
suspect
diseas
condit
contact
appropri
isopeptidas
substrat
invent
follow
detect
fluoresc
level
fluoresc
indic
isopeptidas
activ
sampl
amount
isopeptidas
activ
sampl
compar
amount
isopeptidas
activ
correspond
sampl
healthi
control
wherein
modul
eg
increas
decreas
isopeptidas
activ
sampl
compar
healthi
control
indic
presenc
diseas
disord
inventor
describ
ubiquitinspecif
proteas
cleav
ubiquitin
nonubiquitin
protein
peptid
ubiquitin
join
significantli
report
cleavag
target
ubiquitin
fusion
except
polyubiquitin
without
upper
lower
limit
size
nonubiquitin
portion
ubiquitin
fusion
cleav
peptid
bond
ubiquitin
fusion
protein
carboxytermin
residu
ubiquitin
moieti
group
nonubiquitin
protein
peptid
join
also
recogn
cleav
describ
sandwich
ubiquitin
fusion
ubiquitin
moieti
locat
first
second
nonubiquitin
moieti
project
applic
pertain
protein
peptid
whose
function
activ
inhibit
otherwis
modifi
presenc
ubiquitin
moieti
circumst
ubiquitin
moieti
use
temporari
inhibitor
modifi
activ
protein
peptid
ubiquitinspecif
proteas
employ
restor
deubiquitin
origin
activ
protein
peptid
invent
also
pertain
recombin
vector
express
proteas
cell
transform
vector
specif
version
ubiquitinprotein
fusion
facilit
isol
manipul
nonubiquitin
portion
fusion
use
proteas
inventor
disclos
two
kaposi
sarcomaassociatedherpesviru
peptid
correspond
correspond
potent
select
hausp
antagonist
demonstr
peptid
robustli
suppress
hausp
dub
enzymat
activ
ultim
lead
anticanc
activ
hausp
herp
virusassoci
ubiquitinspecif
proteas
ubiquitin
specif
proteas
deubiquityl
enzym
cleav
ubiquitin
substrat
hausp
play
pivot
role
stabil
rais
hausp
potenti
therapeut
target
tune
antitumor
activ
hausp
wide
known
direct
antagonist
normal
level
kept
low
part
due
ubiquitin
degrad
interestingli
respons
oncogen
insult
hausp
deubiquitin
protect
degrad
respons
stress
also
report
howev
hausp
requir
destabil
disrupt
hausp
stabil
henc
peptid
significantli
suppress
hausp
dub
enzymat
activ
ultim
lead
anticanc
activ
present
disclosur
provid
method
inhibit
growth
acut
lymphoblast
leukemia
cancer
cell
compris
contact
cell
effect
amount
one
peptid
fragment
polynucleotid
composit
therebi
inhibit
growth
cancer
cell
peptid
compris
altern
consist
essenti
yet
consist
cell
penetr
domain
exampl
compris
hiv
tat
peptid
embodi
treatment
compris
administr
polynucleotid
encod
peptid
present
disclosur
antibodi
specif
bind
peptid
present
disclosur
therefor
peptid
along
homologu
use
treat
cancer
particular
acut
lymphoblast
leukemia
regul
activ
cancer
cell
summari
dub
inhibitor
patent
review
see
tabl
shown
copper
biolog
activ
metal
metal
gold
could
use
treatment
varieti
patholog
condit
although
divers
mode
action
includ
limit
inhibit
up
due
abil
bind
copper
inhibit
cellular
proteasom
mani
copperchel
compound
could
induc
apoptosi
tumor
cell
similarli
diethyldithiocarbam
etdtc
coupl
copper
zinc
could
inhibit
purifi
proteasom
intact
proteasom
activ
cancer
cell
interestingli
zincand
copper
etdtc
complex
better
inhibitor
proteasom
proteasom
henc
propos
copper
zinc
complex
act
proteasom
inhibitor
although
mechan
might
differ
clinic
approv
proteasom
inhibitor
bortezomib
possibl
complex
could
inhibit
rather
proteasom
although
need
assess
pyrithion
pt
excel
metal
chelat
copper
complex
cupt
could
inhibit
proteasomespecif
dub
proteasom
peptidas
result
cytotox
vitro
cancer
cell
well
vivo
tumor
xenograft
studi
cupt
could
new
class
dual
inhibitor
dub
although
exact
mechan
clear
yet
proteasom
attract
emerg
target
anticanc
therapi
auranofin
aur
goldcontain
compound
use
treatment
rheumat
arthriti
sinc
research
shown
anticanc
potenti
therefor
recent
approv
phase
ii
clinic
trial
treat
cancer
us
food
drug
administr
http
although
exact
mechan
action
aur
clear
quantit
equal
effect
bortezomib
term
proteasom
inhibitori
properti
mechanist
differ
bortezomib
inhibit
proteasomeassoci
deubiquitinas
dub
like
proteasom
addit
inhibit
requir
cytotox
effect
sever
report
indic
target
show
inhibit
dna
rna
protein
synthesi
well
reactiv
oxygen
speci
ro
mitochondri
thioredoxin
reductas
glutathionestransferas
cathepsin
b
furthermor
vivo
anim
model
aur
show
inhibit
tumor
growth
aur
also
induc
cytotox
cancer
cell
isol
acut
myeloid
leukemia
patient
make
promis
anticanc
drug
due
high
preval
intrins
acquir
resist
pi
addit
preval
extens
advers
effect
eg
peripher
neuropathi
urgent
necess
further
develop
novel
upstarget
inhibitor
could
specif
potent
well
could
circumv
pi
resist
up
consist
profound
dynam
regulatori
system
control
fate
specif
protein
therebi
coordin
dynam
signal
statu
fate
cell
dub
play
promin
specif
role
regul
up
therefor
plausibl
therapeut
target
dub
regul
ubiquitin
state
mani
crucial
molecul
therebi
regul
cellular
pathway
modul
homeostasi
fate
crystal
structur
variou
dub
resolv
provid
addit
evid
dub
inhibitor
may
use
treatment
proteopathi
viral
infect
well
cancer
although
progress
made
understand
dub
biologymechan
consider
work
done
order
move
dub
clinic
basic
research
crucial
discov
natur
regulatori
mechan
cell
order
identifi
candid
pathway
target
requir
regul
dub
express
activ
may
modul
pharmacolog
furthermor
basic
scienc
yet
fulli
understand
system
wide
pharmacodynam
ramif
target
dub
rigor
wellcontrol
studi
must
perform
order
fulli
understand
specif
select
activ
stabil
variou
endogen
dub
normal
patholog
biolog
order
determin
best
target
futur
dubbas
drug
develop
approv
bortezomib
treatment
mm
patient
hematolog
malign
valid
up
establish
potent
chemotherapeut
target
treatment
multipl
cancer
howev
research
studi
reveal
weak
direct
target
proteasom
studi
reveal
high
preval
inher
induc
direct
pi
resist
patient
addit
lack
efficaci
treatment
solid
tumor
well
multipl
advers
effect
result
addit
approach
target
proteasom
andor
compon
proteasom
system
must
pursu
canon
strategi
implement
combat
gener
drug
resist
target
anoth
compon
specif
pathway
ie
upstream
proteasom
degrad
clinician
often
achiev
use
multipl
chemotherapeut
hope
synergi
differenti
target
pathway
review
detail
signific
divers
role
dub
play
protein
turnov
local
cellular
homeostasi
review
also
detail
number
patent
file
compound
target
dub
multitud
mechan
evid
suggest
specif
dub
may
ideal
therapeut
target
provid
valuabl
diagnost
prognost
valu
review
also
view
consider
effort
undertaken
order
develop
novel
dub
modul
howev
clear
understand
basic
biolog
specificityselect
dub
need
specif
dub
inhibitor
identifi
develop
clinic
characterist
make
dub
intrigu
promis
target
cancer
therapi
also
make
predict
downstream
consequ
dubtarget
extrem
complic
dub
exhibit
extraordinarili
dynam
complex
system
regul
cellular
activ
fate
therefor
must
better
understand
role
molecul
order
determin
dub
specif
cancer
role
play
pathway
design
intellig
craft
clinic
target
scheme
base
uniqu
patholog
individu
cancer
type
reason
librari
dub
sumoyl
kinas
phosphatas
countless
molecularmodul
key
pathway
inhibitor
must
identifi
screen
select
specif
efficaci
importantli
safeti
known
cancer
reli
pervers
normal
cellular
process
mani
oncogen
pathway
critic
compon
could
target
chemotherapeut
drug
theoret
mani
target
may
regul
specif
dub
member
up
order
modul
pathway
endogen
research
must
identifi
specif
up
compon
dub
determin
specif
associ
individu
cancer
key
oncogen
dub
identifi
work
begin
identifi
select
inhibitor
target
order
kill
cancer
cell
select
better
understand
dub
function
differenti
regul
normal
physiolog
process
well
role
variou
patholog
condit
delin
driver
bystand
dub
act
tumor
suppressor
promot
result
dub
dynam
activ
target
promiscu
differenti
regul
complet
understand
dub
function
elus
henc
dire
need
depth
character
dub
activ
express
profil
select
specif
moa
order
identifi
role
dub
normal
patholog
context
way
dub
express
profil
might
abl
identifi
patient
group
might
respond
better
specif
dub
inhibitor
addit
cancer
dubtarget
therapi
may
also
benefit
diseas
pathogen
diseas
identif
new
uniqu
member
dub
famili
present
patholog
microorgan
structur
differ
host
dub
suggest
may
possibl
differenti
target
dub
pathogen
organ
inert
host
increas
preval
antibiot
resist
bacteria
microorgan
dub
may
util
novel
specif
antibiot
dub
inhibitor
could
develop
specif
target
pathogen
dub
spare
untoward
effect
host
due
lack
effect
antiinfecti
agent
emerg
resist
strain
inhibitor
dub
patholog
microorgan
pose
potenti
therapeut
target
could
exploit
treat
plant
anim
human
subject
develop
assay
eg
biophys
studi
dubsubstr
interact
done
high
throughput
manner
order
design
dub
regul
refin
enhanc
specif
deliveri
compound
small
molecul
inhibitor
could
use
interfer
interact
dub
substrat
inhibit
catalyt
activ
specif
dub
unfortun
major
current
small
molecul
dub
inhibitor
select
target
multipl
dub
although
yet
prove
compound
target
one
specif
dub
could
clinic
use
like
resist
might
quickli
becom
problem
even
select
specif
inhibitor
howev
possibl
dub
inhibitor
intent
lack
specif
might
benefici
therapeut
target
multipl
critic
protein
multipl
patholog
pathway
dub
inhibitor
could
either
use
prevent
diagnosi
possibl
first
line
therapi
combin
establish
therapeut
agent
high
throughput
method
screen
avail
compound
could
yield
librari
compound
research
may
identifi
key
compound
modifi
enhanc
pharmacodynam
pharmacokinet
profil
librari
select
compound
may
abl
screen
individu
patient
tumor
order
determin
combin
up
modul
targetscompound
would
best
interrupt
preval
activ
pathway
given
cancer
way
cell
proteasom
cellular
machineri
could
util
destroy
crucial
target
thu
kill
cancer
cell
dysregul
high
jack
signal
pathway
cancer
reli
drive
unregul
cellular
process
stratagem
approach
would
path
toward
develop
truli
person
medicin
treatment
cancer
hope
text
could
serv
refer
investig
interest
dubtarget
therapi
understand
compound
avail
dub
research
well
properti
suggest
techniqu
may
use
develop
next
gener
dub
inhibitor
